mProX™ Human PIK3CD Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1222-KX433	Magic™ Human PIK3CD/PIK3R1 in Vitro Assay	Human		Kinase Assay

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;OCI-Ly8

Target Classification

Kinase Cell Lines

Target Research Area

Immunology Research

Related Diseases

Immunodeficiency 14A With Lymphoproliferation, Autosomal Dominant; Immunodeficiency 14B, Autosomal Recessive

Gene ID

Human:5293

UniProt ID

Human:O00329

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

PIK3CD, which encodes the phosphatidylinositol 3-kinase (PI3K) delta subunit, is involved in various biological processes and has been implicated in breast cancer, aplastic anemia, adult T-cell leukemia/lymphoma (ATLL), and activated phosphoinositide 3-kinase delta (PI3KŒ¥) syndrome (APDS). In breast cancer, PIK3CD is part of the PI3K/AKT/HIF-1Œ±/VEGF signaling pathway and is regulated by the natural anti-cancer compound echinacoside (ECH), which inhibits proliferation and induces apoptosis in breast cancer cells. In ATLL, PIK3CD is identified as a potential biomarker and is associated with tumor immune infiltration. In aplastic anemia, PIK3CD is involved in the therapeutic effect of Er-Xian decoction (EXD), which regulates the PI3K-Akt pathway and JAK-STAT pathway. In APDS, leniolisib, a selective PI3KŒ¥ inhibitor, has shown favorable outcomes in patients, reducing infection rates and improving immune cell subsets. Overall, PIK3CD plays a significant role in these diseases and may be a target for therapeutic interventions.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human PIK3CD Stable Cell Line (S01YF-1023-PY54). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Casey Garcia (Verified Customer)

What is the impact of PIK3CD mutations in B cell abnormalities? Nov 15 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

Gain-of-function mutations in PIK3CD can lead to B cell abnormalities, including decreased peripheral B cell numbers and enhanced activation and differentiation of naive B cells. Nov 15 2020

chat Morgan Williams (Verified Customer)

Can genome editing of Pik3cd impede abnormal retinal angiogenesis? Feb 16 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

Editing retinal Pik3cd in a mouse model significantly reduces pathological retinal angiogenesis, suggesting a therapeutic potential for related conditions. Feb 16 2020

Published Data

Fig.1 Significant inhibition of proliferation was achieved through the knock-down of PIK3CD.

Using the MTT approach, the proliferative variation was monitored, and a significant suppression of OCI-LY8 cell proliferation was observed at 72 and 96 hours when PIK3CD was stably knocked down, in comparison with OCI-Ly8 cells transfected with control vectors.

Ref: Cui, Wenli, et al. "PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc." Tumor Biology 37 (2016): 12767-12777.

Pubmed: 27448819

DOI: 10.1007/s13277-016-5225-5

Research Highlights

Liang, Hongyi. et al. "Echinacoside regulates PI3K/AKT/HIF-1α/VEGF cross signaling axis in proliferation and apoptosis of breast cancer." Analytical biochemistry, 2023.
Echinacoside (ECH) has been identified as a potent anti-cancer compound with significant potential in the treatment of cancer. Despite its promising effects, the specific mechanism underlying its anti-cancer properties in breast cancer (BC) remains unclear. Further research and investigation are needed to fully understand the role of ECH in BC treatment and its potential for use in clinical settings.
Liang, Hongyi. et al. "Echinacoside regulates PI3K/AKT/HIF-1α/VEGF cross signaling axis in proliferation and apoptosis of breast cancer." Analytical biochemistry, 2023.
Pubmed: 37865269 DOI: 10.1016/j.ab.2023.115360

He, Wenxing. et al. "PIK3CD correlates with prognosis, epithelial-mesenchymal transition and tumor immune infiltration in breast carcinoma." Discover. Oncology, 2023.
Breast carcinoma (BRCA) is a prevalent and deadly cancer that poses a significant threat to human health. Mounting evidence suggests that PIK3CD plays a crucial role in the onset and progression of various types of cancer. Nonetheless, its specific role and mechanism in BRCA remains poorly understood. Further research is needed to fully uncover the implications of PIK3CD in this aggressive disease.
He, Wenxing. et al. "PIK3CD correlates with prognosis, epithelial-mesenchymal transition and tumor immune infiltration in breast carcinoma." Discover. Oncology, 2023.
Pubmed: 37861728 DOI: 10.1007/s12672-023-00805-0